STOCK TITAN

Axogen (NASDAQ: AXGN) CFO nets shares after option exercises and sales

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Axogen, Inc. CFO Lindsey Marie Hartley reported an option-related share transaction. On May 7, 2026, she exercised employee stock options to acquire a total of 5,463 shares of common stock at exercise prices of $8.20 and $8.27 per share, and sold 1,051 shares in open-market transactions at $43.67 per share. The options exercised were or will be fully vested under schedules that reach full vesting in March 2026 and March 2027, reflecting routine compensation-related activity.

Positive

  • None.

Negative

  • None.
Insider Hartley Lindsey Marie
Role CFO
Sold 1,051 shs ($46K)
Type Security Shares Price Value
Exercise Employee Stock Option (right to purchase) 2,500 $0.00 --
Exercise Employee Stock Option (right to purchase) 2,963 $0.00 --
Exercise Common Stock 2,500 $8.20 $21K
Sale Common Stock 478 $43.67 $21K
Exercise Common Stock 2,963 $8.27 $25K
Sale Common Stock 573 $43.67 $25K
Holdings After Transaction: Employee Stock Option (right to purchase) — 0 shares (Direct, null); Common Stock — 63,234 shares (Direct, null)
Footnotes (1)
  1. All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026. All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
Shares sold 1,051 shares Common stock sold in open market on May 7, 2026
Sale price $43.67/share Price for common stock sales on May 7, 2026
Options exercised 5,463 shares Total underlying common shares from option exercises
Option strike price 1 $8.27/share Exercise price for 2,963-share employee stock option
Option strike price 2 $8.20/share Exercise price for 2,500-share employee stock option
Full vesting date grant 1 March 16, 2026 Date all shares under one option became fully vested
Full vesting date grant 2 March 16, 2027 Scheduled date remaining option grant becomes fully vested
Employee Stock Option (right to purchase) financial
"security_title: "Employee Stock Option (right to purchase)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting schedule financial
"based upon a vesting schedule whereby 50% of the aggregate shares vested"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
fully vested financial
"All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hartley Lindsey Marie

(Last)(First)(Middle)
13631 PROGRESS BLVD.
SUITE 400

(Street)
ALACHUA FLORIDA 32615

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/07/202605/07/2026M2,500A$8.263,234D
Common Stock05/07/202605/07/2026S478D$43.6762,756D
Common Stock05/07/202605/07/2026M2,963A$8.2765,719D
Common Stock05/07/202605/07/2026S573D$43.6765,146D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to purchase)$8.205/07/202605/07/2026M2,500 (1)03/16/2032Common Stock2,500$00D
Employee Stock Option (right to purchase)$8.2705/07/202605/07/2026M2,963 (2)03/16/2033Common Stock2,963$00D
Explanation of Responses:
1. All shares of Axogen, Inc. common stock underlying the employee stock option were fully vested on March 16, 2026.
2. All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.
Remarks:
/s/ Marc Began, as attorney-in-fact for Lindsey Hartley05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Axogen (AXGN) CFO Lindsey Marie Hartley report in this Form 4?

Axogen CFO Lindsey Marie Hartley reported exercising employee stock options and selling some common shares. She acquired 5,463 shares through option exercises and sold 1,051 shares in open-market transactions, all on May 7, 2026, as part of routine equity compensation activity.

How many Axogen (AXGN) shares did the CFO sell and at what price?

The CFO sold 1,051 shares of Axogen common stock in open-market transactions. These sales occurred at a price of $43.67 per share on May 7, 2026, according to the Form 4 transaction details for her non-derivative common stock holdings.

How many Axogen (AXGN) stock options did the CFO exercise and at what strike prices?

She exercised options covering a total of 5,463 shares of Axogen common stock. The underlying employee stock options had exercise prices of $8.20 and $8.27 per share, reflecting previously granted equity awards that were used to acquire additional common shares.

Were the Axogen (AXGN) options exercised by the CFO fully vested?

One option grant was already fully vested as of March 16, 2026. Another grant will be fully vested on March 16, 2027, following a schedule where 50% vested in March 2025 and an additional 12.5% vests every six months thereafter.

Does this Axogen (AXGN) Form 4 show any remaining stock options for the CFO?

The filing records option exercises for two employee stock option grants tied to 5,463 underlying shares and shows no remaining balance for those specific options. The derivative section reflects zero remaining shares for these grants after exercise, indicating those particular awards were fully used.

What type of transactions are reported in this Axogen (AXGN) insider filing?

The Form 4 reports a mix of derivative and non-derivative transactions. It includes option exercises classified as derivative exercises or conversions, and open-market sales of common stock, giving a combined picture of compensation-related activity and partial share dispositions by the CFO.